Rachel Thompson

Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers

1

Total Citations

6

H-Index

1

About

Dr. Rachel Thompson is a leading biotechnologist specializing in mRNA vaccine analytics and quality control. Her primary research focuses on the detection and quantification of process-related impurities in mRNA therapeutics, particularly double-stranded RNA (dsRNA) byproducts generated during in vitro transcription. Dr. Thompson’s major contribution is the development and validation of an automated sandwich ELISA platform that enables high-throughput, sensitive quantitation of residual dsRNA in mRNA vaccine formulations. This work directly addresses a critical safety and potency concern in the rapidly advancing field of mRNA-based medicine. Her landmark 2024 paper on this methodology has already garnered 6 citations, reflecting its immediate relevance to both academic researchers and industrial vaccine manufacturers. By providing a robust, scalable solution for impurity monitoring, Dr. Thompson’s innovations help ensure the consistency and safety of next-generation vaccines, supporting global efforts to combat infectious diseases. Her achievements position her as a key figure in bridging analytical chemistry with cutting-edge vaccine technology.

Research Focus

Key Achievements

1
H-Index
1
Papers
6
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
Development and Application of Automated Sandwich ELISA for Quantitating Residual dsRNA in mRNA Vaccines
6 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago